|
|
Keeping Up with CAR T-cell Therapy: A Case-based Challenge of CART in NHL + MM
Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and... |
|
|
New Guidelines and Novel Treatments for PAH: Taking a Forward-Looking Data Dive Into the Pool of Emerging Therapies
Target Audience
This educational activity has been designed to meet the needs of cardiologists, pulmonologists, rheumatologists, and other physicians, including those in primary care and internal medicine, as well as physician assistants, nurse practitioners, and other healthcare providers who may be involved in managing care for patients with pulmonary arterial hypertension (PAH).
Program Overview
Discoveries about the pathogenesis of pulmonary arterial hypertension (PAH) revealed key mo... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently five drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, rozanolixizumab, and zilucoplan. Clinical trial data on these therapies, as... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology and family practice. Other members of the care team may also participate.
Program Overview
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subt... |
|
|
Beyond Avoidance: IgE-Mediated Food Allergies " Therapeutic Innovations to the Rescue
In the United States, food-induced allergic reactions are the leading cause of anaphylaxis in hospital emergency departments. Among these, immunoglobulin E (IgE)-mediated food allergies are the most common, and they pose significant risks, including cardiac arrest and respiratory failure. Traditionally, treatment options for IgE-mediated food allergies have been primarily limited to food avoidance and anaphylaxis prevention. However, recent years have brought the FDA approval of the first oral... |
|
|
Geographic Atrophy Secondary to Age-Related Macular Degeneration: Innovative Therapies for Sight Revival
Multimodal imaging is key for the early detection and monitoring of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Optical coherence tomography has recently been recommended by an international consensus to be the primary imaging method for the detection of atrophy in eyes. Once diagnosed, timely therapeutic intervention should be initiated with recently FDA-approved therapies that target components of the complement cascade. When optimally integrated into persona... |
|
|
nAMD and DME: Novel Treatment Plans to Prioritize Real-World Visual Improvements
Frequent intravitreal injections of anti-vascular endothelial growth factor (VEGF) therapies can significantly improve visual and anatomical outcomes for many patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, the requisite high number of treatments often leads to less-than-ideal results compared to outcomes reported in major clinical trials, largely due to the demanding treatment schedule. Adopting tailored treatment plans, along with ... |
|
|
Patient‐Centered GA Care: A Synergistic Approach to Optimize Management
The recent FDA approval of 2 novel therapies for the management of patients with geographic atrophy (GA) secondary to age-related macular degeneration has further reenforced the necessity for early GA diagnosis to limit progression. Advances in imaging technologies now provide tools for better detection and characterization of GA, along with biomarkers to monitor progression over time. Optometrists, as front-line eye healthcare providers, play a critical role in the timely diagnosis, managemen... |
|
|
New Guidelines, Emerging Treatments, and Unexpected Patients: Understanding the Challenges of PAH
Target Audience
This activity is designed for nurse practitioners, nurses, and physician assistants who manage patients with or at risk for PAH.
Program Overview
It is a deadly disease and there’s still no cure, but with treatment, survival for patients with pulmonary arterial hypertension (PAH) can be significantly extended. Although rare, nurse practitioners are likely to encounter this cardiopulmonary disorder throughout their careers, and need to be familiar with the multiple dru... |
|
|
Biosimilars in Osteoporosis: Highlights from the ASBMR
Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency.
Incorporating biosimilars into the management of osteoporosis, known as a silent chronic disease responsible for 13 million fragility fractures worldwide, provide a more affordable version of osteoporosis medication, and an alternat... |
|
|
WEBINAR BUNDLE: Compounding Clarity: Decoding USP Standards in Pharmacy Practice Bundle
The Compounding Clarity: Decoding USP Standards in Pharmacy Practice bundle is accredited for 3.0 contact hours (0.3 CEUs) of continuing education credit for pharmacists and pharmacy technicians.
Webinar 1 - GFI #256: How it affects compounding for veterinary patients (2023)
This webinar will help veterinary compounders understand the requirements of GFI-256 and why such a document is necessary in the current federal landscape. Pharmacists and technicians will learn when FDA intends... |
|
|
WEBINAR: Legal Insights into Peptide & Semaglutide Compounding: Navigating FDA, State Boards, and Telemedicine
Compounding peptides and semaglutide comes with unique legal challenges and opportunities. This webinar will break down the latest updates on regulations and provide practical guidance for compounders.
In this 1-hour CE session, our speakers will cover the FDA’s current stance on peptide compounding, key updates from state Boards of Pharmacy, legal considerations with brand manufacturers, the role of telemedicine in compounding, and tips for handling bulk chemical ingredients. |
|
|
Webinar - Pregabalin for Felines
Overview " Transportation anxiety is common in felines and can prevent owners from providing optimal care due to the stress and complications of simply getting to the veterinarian. Human pregabalin, alprazolam, and trazadone are some of the current options prescribed to pet owners to help, but pregabalin has been recently FDA-approved for this use in felines only to provide pet owners an easier time taking care of their loved one that has been studied and researched in felines specificall... |
|
|
WEBINAR: Pregabalin for Felines
Overview: Transportation anxiety is common in felines and can prevent owners from providing optimal care due to the stress and complications of simply getting to the veterinarian. Pregabalin, alprazolam, and trazodone, FDA approved for human use, are some of the current options prescribed to help with transportation anxiety. Recently, pregabalin has been FDA-approved for this indication exclusively for feline patients. The purpose of this knowledge-based activity is to review pregabalin primar... |
|
|
WEBINAR: Introduction to Homeopathic Medicines for Veterinary Pharmacists
Overview " Homeopathic medicines have been used for over 200 years in humans, plants, and animals. They have been recognized as drugs by the FDA since 1938 and are easily accessible over-the-counter in all markets. The use of homeopathic medicines continues to grow in popularity, yet many misconceptions still circulate about their efficacy and safety. Many pharmacists lack training on homeopathic medicines, but pharmacists have an obligation to be well-informed about the strengths and lim... |
|
|
WEBINAR: DSCSA - 13 Year Implementation & 2024 Update
The Drug Supply Chain Security Act (DSCSA), enacted in 2013, is approaching its final implementation phase. This 1-hour CE session will review the step-by-step implementation process and provide an important update for 2024 and beyond.
By November 27, 2026, pharmacies must comply with FDA enforcement requirements to electronically exchange transaction information and conduct package-level verification. This involves implementing systems for serialized transaction data, ensuring quick access... |
|
|
Optimizing Sterile Compounding: From Aseptic Processing to FDA Compliance
Equip your pharmacy team with essential knowledge through this 4-hour accredited CE virtual course. Explore topics such as aseptic processing, terminal sterilization methods, release testing (visual inspections, sterility, endotoxin), FDA guidance documents, component selection, and the importance of certificates of analysis. This course ensures your team stays compliant and confident in sterile compounding practices. Schedule your pharmacy team today!
Learning Objectives:
1. Discuss... |
|
|
Therapy Tidbits Summer 2021
Therapy Tidbits – Summer 2021 is a 1-hour online continuing education (CE) course comprised of select articles from the Summer 2021 issue of The National Psychologist, a private, independent, quarterly newspaper intended to keep psychologists informed about practice issues. The articles included in this course are:
• Improving Health through Community Policies Gains Momentum – Provides an overview of the Blue Zone Project and the impact on community members’ health.
• Psychologis... |
|